HealthEquity Q2 2025 Adj. EPS $0.86 Beats $0.70 Estimate, Sales $299.928M Beat $284.870M Estimate
Portfolio Pulse from Benzinga Newsdesk
HealthEquity reported strong Q2 2025 results, with adjusted EPS of $0.86 beating estimates by 22.86% and sales of $299.928M surpassing expectations by 5.29%. This marks a 23.15% increase in sales compared to the same period last year.
September 03, 2024 | 8:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HealthEquity's Q2 2025 earnings and sales significantly exceeded analyst expectations, with EPS at $0.86 and sales at $299.928M, indicating strong financial performance and growth.
HealthEquity's earnings per share and sales both exceeded analyst estimates by significant margins, indicating strong financial health and potential for stock price appreciation. The 23.15% year-over-year sales growth further underscores the company's positive trajectory.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100